Aglaia Oncology Announces Sale of Portfolio Company Syntarga BV
6/23/2011 10:50:52 AM
More...
|
Synthon Acquires Syntarga BV and its Antibody-Drug Conjugate Technology
6/23/2011 10:07:38 AM
More...
|
Syntarga BV Announces New Antibody-Drug Conjugate Collaborations
4/7/2011 9:37:31 AM
More...
|
Syntarga BV Announces Additional Antibody-Drug Conjugate Collaborations
6/1/2010 12:42:17 PM
More...
|
Syntarga BV Announces Two Antibody-Drug Conjugate Collaborations with Top-tier Biopharmaceutical Companies
3/4/2010 2:04:24 PM
More...
|
Syntarga BV Announces Patent Grant for SpaceLink Technology for Antibody-Drug Conjugation
7/16/2009 12:31:39 PM
More...
|
Syntarga BV Demonstrates In Vivo Proof of Concept for its Antibody-Drug Conjugate Technology
1/8/2009 12:12:35 PM
More...
|
Syntarga BV Appoints Antibody-Drug Conjugate expert Dr. Nitin Damle as Advisor
7/21/2008 2:28:03 PM
More...
|
Syntarga BV Licenses Potent Cell-Killing Drugs From The University Of Göttingen, Germany
3/15/2006 2:07:59 PM
More...
|
Syntarga BV Closes Series A Financing
10/19/2005 5:12:42 PM
More...
|